NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund researchers seeking to develop and validate biomarkers that can be used to detect and predict progression of hematopoietic malignancies, such as Hodgkin and non-Hodgkin lymphoma, leukemia, multiple myeloma, and others.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.